Core Viewpoint - Fengbei Biotechnology Co., Ltd. has successfully listed on the Shanghai Stock Exchange, with a significant opening price increase and high trading volume, indicating strong market interest and investor confidence in the company [1]. Company Overview - Fengbei Biotechnology is a high-tech enterprise focused on the comprehensive utilization of waste resources, primarily producing resource-based products from waste oils [2]. - The controlling shareholder and actual controller of the company is Pingyuan, who directly holds 44.82% of the shares post-IPO and controls a total of 64.03% of the shares through indirect holdings [2]. Financial Performance - The company reported revenues of 170,869.32 million yuan, 172,778.32 million yuan, and 194,801.63 million yuan for the years 2022, 2023, and 2024 respectively, showing a steady growth trend [6]. - Net profits attributable to the parent company were 13,334.79 million yuan, 12,971.18 million yuan, and 12,381.99 million yuan for the same years, indicating a slight decline in profitability [6]. - For the first nine months of 2025, the company achieved revenues of 225,140.52 million yuan, a year-on-year increase of 62.32%, and a net profit of 11,729.88 million yuan, up 35.32% from the previous year [8][9]. IPO Details - The company issued 35.90 million new shares at an issue price of 24.49 yuan per share, raising a total of 879.191 million yuan, with a net amount of 794.438 million yuan after deducting issuance costs [4]. - The funds raised will be used for projects including the construction of production facilities for various bio-based products [4][5]. Future Outlook - The company plans to adjust its customer and product structure in 2024 while maintaining revenue growth, with a focus on managing sales and administrative expenses effectively [3]. - There are inquiries regarding the sustainability of revenue from biofuels and the growth potential of industrial-grade mixed oil sales, indicating a need for careful monitoring of market conditions and operational stability [3].
丰倍生物募资8.8亿首日涨173% 经营现金净额连深跌